Comparing the effect of high-intensity laser therapy (HILT) and targeted radiofrequency therapy (TRT) on muscle tone in the cervical and thoracic regions. The research aims to determine the effectiveness of the effect of novel physical therapy on the change of muscle tone in the cervical and thoracic region. This is an intervention experiment applied to a group of 60 probands.

Start Date01 Nov 2022

Sponsor / Collaborator

University of Charles

CTR20222644 / CompletedNot Applicable

布洛芬颗粒在健康受试者中空腹/餐后单次口服给药、随机、开放、两制剂、两周期、交叉生物等效性试验

[Translation] A single oral fasting/fed, randomized, open-label, two-formulation, two-period, crossover bioequivalence study of ibuprofen granules in healthy volunteers

主要目的：考察中国健康受试者在空腹/餐后条件下单剂量口服四川依科制药有限公司生产的布洛芬颗粒（规格：0.2g）与 Kaken Pharmaceutical Co., Ltd.生产的布洛芬颗粒（规格：20%1g）的体内药代动力学特征，评价四川依科制药有限公司生产的布洛芬颗粒（规格：0.2g）与Kaken Pharmaceutical Co., Ltd.生产的布洛芬颗粒（规格：20%1g）制剂的生物等效性。次要目的：评价单剂量口服布洛芬颗粒（规格：0.2g）受试制剂及参比制剂在中国健康受试者中的安全

[Translation]

Primary objective: To investigate the in vivo pharmacokinetic characteristics of ibuprofen granules (specification: 0.2g) produced by Sichuan Yike Pharmaceutical Co., Ltd. and ibuprofen granules (specification: 20%1g) produced by Kaken Pharmaceutical Co., Ltd. after single oral administration under fasting/postprandial conditions in healthy Chinese subjects, and to evaluate the bioequivalence of ibuprofen granules (specification: 0.2g) produced by Sichuan Yike Pharmaceutical Co., Ltd. and ibuprofen granules (specification: 20%1g) produced by Kaken Pharmaceutical Co., Ltd. Secondary objective: To evaluate the safety of the test and reference preparations of single oral ibuprofen granules (specification: 0.2g) in healthy Chinese subjects

Start Date08 Oct 2022

Sponsor / Collaborator

Si Chuan Shu Zhong Zhi Yao You Xian Gong Si

100 Clinical Results associated with Cervicobrachial syndrome

100 Translational Medicine associated with Cervicobrachial syndrome

0 Patents (Medical) associated with Cervicobrachial syndrome

100

Literatures (Medical) associated with Cervicobrachial syndrome

03 Jul 2024·Journal of Manual & Manipulative Therapy

Rethinking neck-related arm pain: hypothetical clinical scenarios to differentiate the underlying IASP-defined pain mechanisms

Review

Author: Dierick, Frédéric ; Roussel, Nathalie ; Fourré, Antoine ; Da Natividade, Joël ; Hage, Renaud ; Jones, Mark

Neck-related arm pain is frequently encountered in clinical settings, yet its underlying pain mechanisms remain elusive. While such pain radiating from the neck to the arm is often attributed to injuries or diseases of the nervous system (neuropathic pain), it can also arise from nociceptive (referred) or nociplastic sources. Regrettably, patients exhibiting this specific pain distribution are frequently diagnosed with varying terms, including 'cervicobrachialgia', 'cervicobrachial neuralgia', 'cervicobrachial pain syndrome', and 'cervical radiculopathy'. The ambiguity surrounding these diagnostic labels complicates the clinical reasoning process. It is imperative for clinicians to discern and comprehend the dominant pain mechanism. Three distinct hypothetical clinical scenarios depict patients with almost identical pain distribution but divergent dominant pain mechanisms. Within these scenarios, both subjective and objective examinations are employed to elucidate the dominant pain mechanism associated with neck-related arm pain: nociceptive, neuropathic, and nociplastic. Furthermore, clinicians must remain aware that the dominant pain mechanism can evolve over time.

16 Feb 2024·Cureus

MRI-Guided Focused Ultrasound for the Treatment of Dystonia: A Narrative Review

Review

Author: Natalwala, Ammar ; Taira, Takaomi ; Bulstrode, Harry ; Momin, Sheikh Muktadir Bin ; Aquilina, Kristian ; Kalia, Suneil

Contemporary surgical management of dystonia includes neuromodulation via deep brain stimulation (DBS) or ablative techniques such as radiofrequency (RF) ablation. MRI-guided focused ultrasound (MRgFUS) is an emerging modality that uses high-intensity ultrasound to precisely ablate targets in the brain; this is incisionless, potentially avoiding the surgical risks of a burr hole and transcortical tract to reach the anatomical target. There is some evidence of efficacy in essential tremor and Parkinson's disease (PD), but, to date, there is no study aggregating the evidence of MRgFUS in dystonia. In this narrative review, we searched Medline, Embase, CINAHL, EBSCO, and ClinicalTrials.gov for primary studies and clinical trials on MRgFUS in the treatment of dystonia. Data were analyzed concerning dystonia phenotype, reported outcomes, and complications. PD-related dystonia was also included within the scope of the review. Using our search criteria, six articles on the use of MRgFUS in adult dystonia and three articles on the use of FUS in dystonia in PD were included. Four trials on the use of FUS in dystonia were also found on ClinicalTrials.gov, one of which was completed in December 2013. All included studies showed evidence of symptomatic improvement, mostly in focal hand dystonia; improvements were also found in dystonia-associated tremor, cervicobrachial dystonia, and dystonia-associated chronic neuropathic pain as well as PD-related dystonia. Reported complications included transient neurological deficits and persistent arm pain in one study. However, the evidence is limited to level-4 case series at present. MRgFUS is an emerging modality that appears to be safe and effective, particularly in focal hand dystonia, without major adverse effects. However, the quality of evidence is low at present, and long-term outcomes are unknown. High-quality prospective studies comparing MRgFUS to other surgical techniques will be useful in determining its role in the management of dystonia.

01 Dec 2023·Journal of Orthopaedic Science

A nationwide multicenter study of the cost effectiveness of five leading drugs for pharmacological management of cervicobrachial symptoms

Article

Author: Hongo, Michio ; Imajo, Yasuaki ; Inoue, Gen ; Haro, Hirotaka ; Miyagi, Masayuki ; Miyamoto, Hiroshi ; Mori, Kanji ; Hashizume, Hiroshi ; Arima, Hideyuki ; Yamato, Yu ; Yoshii, Toshitaka ; Kawakami, Mamoru ; Yagi, Mitsuru ; Nakashima, Hiroaki ; Kobayashi, Kazuyoshi ; Chikuda, Hirotaka ; Kaito, Takashi ; Iizuka, Yoichi ; Suzuki, Satoshi ; Murotani, Kenta ; Kanbara, Shunsuke ; Nagata, Keiji ; Suzuki, Akinobu ; Miyazaki, Masashi ; Tsushima, Mikito ; Koda, Masao ; Imagama, Shiro ; Matsuyama, Yukihiro ; Furuya, Takeo ; Miyakoshi, Naohisa ; Takahata, Masahiko ; Wakao, Norimitsu ; Watanabe, Kei

BACKGROUNDCervicobrachial pain frequently affects the quality of life (QOL) of the general public and has a significant economic impact on the health care systems of various countries. There are a number of treatment options for this disease, including widely-used drug therapy, but the effectiveness of each option is indeterminate, and there have been no published cost-effectiveness analysis studies so far. This prospective observational study aimed to examine the cost-effectiveness of drug treatment for cervicobrachial symptoms.METHODSA 6-month medication regimen for each of five frequently-prescribed drugs for cervicobrachial symptoms was administered to 322 patients at 24 centers in Japan. Outcome measures, including of the EuroQol Group 5D, Short Form-8, and Visual Analog Scale (VAS), were investigated at baseline and every month thereafter. Incremental cost-effectiveness ratios (ICERs) of the drug cost to quality-adjusted life years (QALYs) were calculated. A stratified analysis of patient characteristics was also performed to identify baseline factors potentially affecting cost-effectiveness.RESULTSThe ICER of entire drug treatment for cervicobrachial symptoms was 7,491,640 yen. Compared with the reference willingness-to-pay, the ICER was assumed to not be cost-effective. A certain number of QALYs were gained during the first 3 months after the treatment intervention, but almost no QALYs were gained during the following 3 months. Stratified analysis showed that cost-effectiveness was extremely low for patients with high baseline VAS and high QOL.CONCLUSIONSThe available medications for cervicobrachial symptoms did not have excellent cost-effectiveness. Although a certain number of QALYs were gained during the first 3 months after medication, no QALYs were gained in the latter half of the study period, suggesting that it is not advisable to continue the medication needlessly.LEVEL OF EVIDENCEII, prospective cohort study.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cervicobrachial syndrome

Basic Info

Related

Analysis